Specifically, the PDE4D subfamily has been proposed as a therapeutic target for AD given reported cognitive-enhancing effects of PDE4D inhibitors that are able to avoid negative gastro-intestinal side-effects of other PDE4 inhibitors (Bruno et al., 2011; Tibbo et al., 2019). The gene discussed is PDE4D; the disease is Alzheimer disease.